Sold as Cefobid, Cefobid In Plastic Container. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 16, 2026, FDA lists 3 applications for Cefoperazone Sodium (sold as Cefobid, Cefobid In Plastic Container), first approved Nov 18, 1982, with 0 new uses approved and 0 published complete response letters.
| Impact of Hypoalbuminemia on Cefoperazone/Sulbactam Induced Coagulopathy in Post-Operative Surgical PatientsCefoperazone/Sulbactam Induced Coagulopayjy · Sheikh Zayed Federal Postgraduate Medical Institute | — | Not yet recruiting | Aug 19, 2026 |
| Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill PatientsAcinetobacter Baumannii Infection · Cairo University | Not applicable | Recruiting | Aug 12, 2025 |
| Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical ApplicationIntracranial Infection, Central Infection · Xueyan Cui | — | Active, not recruiting | Dec 11, 2024 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA